Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

119.00DKK
4:21am EDT
Change (% chg)

kr.-1.00 (-0.83%)
Prev Close
kr.120.00
Open
kr.120.00
Day's High
kr.120.00
Day's Low
kr.119.00
Volume
3,919
Avg. Vol
110,219
52-wk High
kr.141.00
52-wk Low
kr.85.50

Latest Key Developments (Source: Significant Developments)

Zealand Pharma to cooperate with Torrey Pines Institute for Molecular Studies
Wednesday, 4 Oct 2017 05:29am EDT 

Oct 4 (Reuters) - ZEALAND PHARMA A/S :REG-ZEALAND PHARMA AND TORREY PINES INSTITUTE FOR MOLECULAR STUDIES ANNOUNCE RESEARCH COLLABORATION.‍PARTIES TO COOPERATE IN ORDER TO IDENTIFY NOVEL PEPTIDE THERAPEUTICS USING TPIMS'S PROPRIETARY PEPTIDE LIBRARIES​.  Full Article

Edge Therapeutics appoints Rosemary Crane to Board of Directors
Tuesday, 19 Sep 2017 07:00am EDT 

Sept 19 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics appoints Rosemary A Crane, pharmaceutical industry leader, to its Board Of Directors.Edge Therapeutics Inc - ‍Crane's appointment expands Board of Directors to 10 members, eight of whom are independent​.Edge Therapeutics Inc - ‍Crane currently serves as a Director of Teva Pharmaceuticals and as vice chairman of Board of Zealand Pharma A/S​.  Full Article

Zealand Pharma and Orbit Discovery enter into research collaboration
Thursday, 7 Sep 2017 04:07am EDT 

Sept 7 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND AND ORBIT DISCOVERY ENTER INTO RESEARCH COLLABORATION.ZEALAND PHARMA A/S - ‍ZEALAND AND ORBIT ANNOUNCE THAT THEY ENTERED INTO MULTI-TARGET RESEARCH COLLABORATION TO IDENTIFY PEPTIDE THERAPEUTICS USING ORBIT'S PEPTIDE DISPLAY TECHNOLOGY​.  Full Article

Zealand Pharma Q2 operating loss widens to DKK 94.8 mln
Thursday, 24 Aug 2017 08:58am EDT 

Aug 24 (Reuters) - ZEALAND PHARMA A/S ::H1 REVENUE OF DKK 88.4 MILLION/USD 13.6 MILLION (DKK 14.7 MILLION/USD 2.2 MILLION IN FIRST HALF OF 2016).Q2 REVENUE DKK 10.8 ‍​ MILLION VERSUS DKK 7.9 MILLION YEAR AGO.‍FINANCIAL GUIDANCE FOR 2017 UNCHANGED​.Q2 OPERATING LOSS DKK 94.8 ‍​MILLION VERSUS LOSS DKK 88 MILLION YEAR AGO.  Full Article

Zealand Pharma partner starts Phase 1 trials for two novel treatments
Tuesday, 22 Aug 2017 09:45am EDT 

Aug 22 (Reuters) - ZEALAND PHARMA A/S ::PHASE 1 TRIALS FOR TWO NOVEL TREATMENTS OF OBESITY AND/OR DIABETES INITIATED BY ZEALAND PARTNER BOEHRINGER INGELHEIM.ZEALAND TO RECEIVE A EUR 4 MILLION (DKK 30 MILLION) MILESTONE PAYMENT RELATED TO INITIATION OF PHASE 1 WITH LONG-ACTING AMYLIN ANALOG.RESULTS ARE EXPECTED IN LATE 2018 ON BOTH COMPOUNDS.  Full Article

Zealand Pharma ADS open at $18.12 in debut vs IPO price of $17.87
Wednesday, 9 Aug 2017 10:01am EDT 

Aug 9 (Reuters) - :Zealand Pharma ADS open at $18.12 in debut on Nasdaq versus IPO price of $17.87 per ADS.  Full Article

Zealand Pharma A/S sees IPO of upto 3.9 mln American depositary shares, representing 3.9 mln shares - SEC FILING
Tuesday, 1 Aug 2017 05:18pm EDT 

Aug 1 (Reuters) - Zealand Pharma A/S :Zealand Pharma A/S sees IPO of up to 3.9 million American depositary shares, representing 3.9 million shares - SEC filing.Zealand Pharma a/s says it adds Guggenheim securities and Needham & Company to underwriters to IPO.  Full Article

Zealand reports Q2 royalty revenue of DKK 9.1 mln
Monday, 31 Jul 2017 01:35am EDT 

July 31 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE SECOND QUARTER OF 2017.ZEALAND REPORTS ROYALTY REVENUE OF DKK 9.1 MILLION IN Q2 2017.  Full Article

Zealand Pharma files for U.S. IPO of up to $86.3 mln
Thursday, 6 Jul 2017 05:31pm EDT 

July 6 (Reuters) - Zealand Pharma A/S ::Zealand Pharma a/s files for u.s. Ipo of up to $86.3 million - sec filing.Zealand Pharma says it has applied to list the ads on Nasdaq under the symbol "zlnd".Zealand Pharma says Morgan Stanley and Goldman Sachs are underwriters to the IPO.  Full Article

Zealand Pharma: phase 2a trial results support development of dasiglucagon
Thursday, 22 Jun 2017 02:50am EDT 

June 22 (Reuters) - ZEALAND PHARMA A/S :PHASE 2A TRIAL RESULTS SUPPORT DEVELOPMENT OF DASIGLUCAGON IN ILET PUMP SYSTEM FOR TYPE 1 DIABETES.IN PHASE 2A TRIAL, DASIGLUCAGON TOGETHER WITH INSULIN WAS OBSERVED TO BE EFFECTIVE IN CONTROLLING BLOOD SUGAR.TRIAL PROVIDES FOUNDATION FOR FURTHER CLINICAL DEVELOPMENT OF DASIGLUCAGON IN ILET(TM) PUMP SYSTEM IN OUT-PATIENT TRIALS.  Full Article

Photo

New Zealand forestry a first test in nationalist party's protectionist agenda

WELLINGTON Some New Zealand forest owners are suspending replanting of trees and re-thinking investments as the country's third-largest export earner finds itself in the sights of maverick politician Winston Peters' protectionist agenda.